Autolus Therapeutics plc (NASDAQ:AUTL) shares rose 3.19% in pre-market trading on Tuesday after the biotechnology company delivered better-than-expected second-quarter results and raised its full-year revenue guidance for AUCATZYL.
Autolus reported a loss of $0.15 per share, narrower than the consensus forecast for a $0.23 loss. Revenue reached $45.7 million, comfortably exceeding the $30.1 million analyst estimate and rising 119% from $20.9 million a year earlier.
The combination of stronger sales and an upgraded outlook puts the progress of the AUCATZYL commercial launch firmly in focus for investors.
Autolus raises AUCATZYL revenue guidance
Autolus increased its full-year 2026 net product revenue forecast for AUCATZYL to between $140 million and $150 million, compared with its previous range of $120 million to $135 million.
The revised midpoint of $145 million indicates that management now expects stronger product sales than previously anticipated.
Second-quarter net product revenue reached $45.7 million, up from $26.2 million in the first quarter of 2026.
Autolus attributed the sequential growth to increased use within existing authorised treatment centres, the addition of new centres and sales in the UK during the product’s second quarter on the market there.
“In the second quarter we achieved substantial sales growth in the ongoing AUCATZYL launch, driven by physician enthusiasm and expanding product use within existing authorized treatment centers, as well as the addition of new centers coming online,” said Dr. Christian Itin, Chief Executive Officer.
Gross margin improves sharply as production scales
The improving economics of AUCATZYL production provided another positive signal from the quarter.
Gross margin increased to 55% from just 6% in the first quarter, with Autolus citing lower manufacturing costs per batch and higher production volumes.
That improvement may become increasingly important as investors assess whether rising AUCATZYL sales can translate into better overall financial performance.
Autolus also narrowed its quarterly net loss to $39.1 million from $47.9 million in the same period last year.
Research and development expenses were relatively stable at $27.9 million compared with $27.4 million a year earlier. Selling, general and administrative expenses increased to $41.2 million from $30.3 million, primarily reflecting commercialisation activities in the U.S. and UK.
New credit facility extends Autolus funding runway
Autolus has also strengthened its available financing as it continues the AUCATZYL rollout.
The company secured a five-year credit facility of up to $250 million with Perceptive Advisors, with $75 million funded when the agreement closed on July 30, 2026.
Autolus expects its cash, cash equivalents and marketable securities, together with anticipated AUCATZYL revenue and proceeds from the credit facility, to fund operations into the second quarter of 2028.
For investors, the key development is that AUCATZYL is generating stronger-than-previously-expected revenue while manufacturing economics are improving. The higher guidance provides evidence of commercial momentum, although continued spending on the launch means sales growth and margin progression will remain important measures of execution.
Autolus Therapeutics stock price
